Brokers Offer Predictions for Reviva Pharmaceuticals Holdings, Inc.’s Q1 2025 Earnings (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Reviva Pharmaceuticals in a research report issued on Monday, April 22nd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.24) EPS and Q4 2025 earnings at ($0.21) EPS.

Separately, Benchmark reiterated a “speculative buy” rating and set a $17.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 16th.

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $3.02 on Tuesday. Reviva Pharmaceuticals has a 1-year low of $2.67 and a 1-year high of $9.25. The business has a 50 day simple moving average of $3.57 and a two-hundred day simple moving average of $4.10. The stock has a market capitalization of $84.32 million, a PE ratio of -1.84 and a beta of -0.02.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC lifted its position in Reviva Pharmaceuticals by 194.0% in the fourth quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after buying an additional 1,164,000 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of Reviva Pharmaceuticals in the fourth quarter valued at $72,000. Finally, EMC Capital Management boosted its stake in shares of Reviva Pharmaceuticals by 1,294.3% during the 3rd quarter. EMC Capital Management now owns 123,915 shares of the company’s stock worth $613,000 after purchasing an additional 115,028 shares during the period. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.